PLUVICTO: The first and only PSMA-targeted RLT now approved after only 1 ARPI1
PLUVICTO targets PSMA, a biomarker overexpressed in more than 80% of men with prostate cancer1,3,4
In the PSMAfore trial after only 1 ARPI,
PLUVICTO more than doubled median rPFS vs a change in ARPI2
Updated exploratory analysis: Median rPFS was 11.6 months with PLUVICTO vs 5.6 months with a change in ARPI (HR=0.49 [95% CI, 0.39-0.61])2,†
PLUVICTO has a favorable safety profile and proven tolerability2
Grade ≥3 AE rates were lower in the PLUVICTO group with a longer median duration of exposure2
6% permanent discontinuation rate due to an AE; 4% had a dose modification due to an AE; 12% had a dose interruption due to an AE1,2
Most common ARs (≥20%) in PSMA+ mCRPC after 1 ARPI: dry mouth, fatigue, nausea, constipation, decreased appetite, and arthralgia1
PLUVICTO can be delivered within 5 days of order placement,‡ so your patients can begin treatment as soon as possible5
Choose PLUVICTO: Proven in 2 large phase 3 trials and ~20K patients treated from launch to date1,2,6,7,§
*For patients considered appropriate to delay taxane-based chemotherapy.1
†Exploratory rPFS analysis was performed with a median follow-up period of 24 months vs the primary analysis at 7 months. This analysis was not controlled for Type-I error.2
‡Exceptions may apply for syringe form and select geographic locations.5
§Based on data from February 2025.